SESSION TITLE: Obstructive Lung Diseases 2 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2018 01:00 PM - 02:00 PM PURPOSE: Although pharmacologic agents are available to manage symptoms in patients with COPD, appropriately selecting from the range of inhaled therapies is challenging and the disease remains uncontrolled in many patients. The purpose of this study is to determine whether an online educational intervention can effectively address knowledge gaps regarding the role of emerging evidence from COPD clinical trials, and recently-issued guidelines, in selecting appropriate inhaled therapies. METHODS: The intervention consisted of an interactive video-based discussion between two experts with synchronized slides. The intended audience was pulmonologists and PCPs who treat patients with COPD. For each intervention, the educational impact was assessed using a 3-question repeated pairs, pre-/post-assessment survey. Data collected from 6/23/2017 through 7/27/2018. Statistical analyses comprised a paired (within-physician) 2-tailed t-test and McNemar’s χ2 statistic, with Cramer’s V used to determine the overall effect of each intervention. RESULTS: Analysis of pre- vs post-intervention responses demonstrated a significant improvement (P <.05) in overall knowledge with considerable educational impact among both pulmonologists and PCPs (V = .180 to .233). Participation in the intervention resulted in increased knowledge in several specific areas of COPD management evidence and guidelines. The absolute percentage increases in correct individual responses (pre- to post-) to questions on these topics among pulmonologists (n=65) and PCPs (n=146) included:GOLDEN trials of nebulized long-acting muscarinic receptor antagonist (LAMA): Pulmonologists +23% (62% to 85%, P < .05), PCPs +33% (40% to 73%, P < .05)TRINITY trial of closed triple therapy (inhaled corticosteroid (ICS)/long-acting beta agonist (LABA)/LAMA): Pulmonologists +15% (65% to 80%, P < .05), PCPs +14% (42% to 56%, P < .05)GOLD 2017 recommended treatments based on case presentation: Pulmonologists +6% (86% to 92%, P=.258), PCPs +24% (38% to 62%, P < .05)With respect to GOLD 2017 recommendations, a higher number of PCPs opted to select an ICS outside of guidelines when compared to pulmonologists (25% vs 3%)The activity was confidence building, with 15% of pulmonologists and 43% of PCPs stating that they were more confident after activity participation in formulating needed individualized treatment for patients with COPD. CONCLUSIONS: Participation in an interactive video-based discussion between two experts with synchronized slides was associated with significant improvement in knowledge of pulmonologists and PCPs in several important aspects of COPD management. Based on residual gaps, further education on COPD therapeutics and clinical trial data for pulmonologists and PCPs is warranted. CLINICAL IMPLICATIONS: Improved knowledge regarding expert recommendations in COPD management is anticipated to lead to improved treatment decision-making DISCLOSURES: No relevant relationships by Karen Badal, source=Web Response No relevant relationships by Piyali Chatterjee, source=Web Response Advisory Committee Member relationship with Mylan Inc Please note: $1001 - $5000 Added 03/02/2018 by James Donohue, source=Web Response, value=Honoraria Removed 03/02/2018 by James Donohue, source=Web Response Advisory Committee Member relationship with Sunovion Pharmaceuticals Please note: $1001 - $5000 Added 03/02/2018 by James Donohue, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Mylan Inc Please note: $1001 - $5000 Added 03/02/2018 by James Donohue, source=Web Response, value=Consulting fee No relevant relationships by Edward Jackson, source=Web Response No relevant relationships by Nimish Mehta, source=Web Response